1-phenyl-3-(3-(trifluoromethyl)phenyl)-1H-pyrazole

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 1-phenyl-3-(3-(trifluoromethyl)phenyl)-1H-pyrazole
• 英文别名: 1-Phenyl-3-[3-(trifluoromethyl)phenyl]pyrazole
• 化学式: C₁₆H₁₁F₃N₂
• 分子量: 288.272
• InChiKey: FZXJRGZCZCKZLS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  21
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  17.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  间三氟甲基苯丙酮 、 苯肼 在 2,2,6,6-四甲基哌啶氧化物 、 copper diacetate 、 溶剂黄146 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 48.0h， 以59%的产率得到1-phenyl-3-(3-(trifluoromethyl)phenyl)-1H-pyrazole
  参考文献：
  名称：

  铜促进的苯丙酮和芳基肼偶联用于合成 1,3-二芳基吡唑

  摘要：

  从商业底物和/或简单转化合成 1,3-二芳基吡唑仍然被低估。在本报告中，我们开发了一种铜促进苯丙酮和芳基肼偶联的方法。在 TEMPO 氧化剂、乙酸添加剂和 DMF 溶剂存在下，反应得到取代的吡唑。许多官能团与反应条件兼容，包括卤素、甲氧基、三氟甲基和硝基。如果使用贫电子苯丙酮，可以获得吲唑。

  DOI：

  10.1055/s-0039-1690835

文献信息

• [EN] PYRAZOLE DERIVATIVES AS MODULATORS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS<br/>[FR] COMPOSES ET COMPOSITIONS DE MODULATION
  申请人：CAREX SA

  公开号：WO2004043951A1

  公开（公告）日：2004-05-27

  The present invention relates to compounds, compositions and methods useful for modulating nuclear receptors activity in cells, and for treating and/or preventing various diseases and conditions mediated by said nuclear receptors, including metabolic or cell proliferative disorders. According to particular aspects, the present invention relates to compounds, compositions and methods useful for modulating activities of the Peroxisome Proliferator Activated Receptors (PPARs) and for treating and/or preventing various disease and conditions mediated by said nuclear receptors. More specifically, it relates to Peroxigome Proliferator Activated Receptor-gamma (PPAR-gamma) ligands, which are useful in the modulation of blood glucose levels and in the increase of insulin sensitivity in patients in need thereof. The properties of the compounds and compositions of the invention make these PPAR ligands particularly useful in the treatment of those diseases and conditions including diabetes, atherosclerosis, hyperglycemia, dyslipidemia, obesity, syndrome X, insulin resistance, hypertension, neuropathy, microvascular diseases (e.g. retinopathy, nephropathy), macrovascular diseases (e.g. myocardial infarction, stroke, heart failure) in mammals.